Phase 4 Elagolix vs OCPs Endometriosis Pain Clinical Trial NCT07532876

NIH registered a new Phase 4 clinical trial (NCT07532876) on ClinicalTrials.gov comparing Elagolix versus oral contraceptive pills for reducing endometriosis-associated pelvic pain. The study is categorized as Phase 4 (post-marketing surveillance) with an anticipated start date and open-label design. The trial will study patients with diagnosed endometriosis using two distinct interventions: Elagolix (an oral GnRH antagonist) and oral contraceptives.\n\nHealthcare providers and clinical investigators involved in endometriosis treatment or women's health research should note this comparative effectiveness study. The trial's findings could inform future prescribing practices and clinical guidelines for managing endometriosis-associated pelvic pain. Patients seeking treatment options may benefit from awareness of this ongoing comparative research between GnRH antagonist therapy and hormonal contraceptives.